Drug Information

Cancer Monthly > Drug Information
Back

Doxil

Brand Name:Doxil Trade Name:doxorubicin liposomal
FDA Approved For:1. The treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment. 2. The treatment of AIDS-related Kaposi’s sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. These indications are based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, such as improvement in disease-related symptoms or increased survival.Pediatric Use:The safety and effectiveness of Doxil® in pediatric patients have not been established.
Carcinogen:Secondary acute myelogenous leukemia has been reported in patients treated with topoisomerase II inhibitors, including anthracyclines. Although no studies have been conducted with Doxil®, doxorubicin HCl and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models.Mutagen:Although no studies have been conducted with Doxil®, doxorubicin HCl and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models.
Manufacturer and/or Distributor:Sequus Pharmaceuticals, Inc.

Adverse Reactions:

For a complete list of adverse reactions please click on the link "More Information" for this drug.)

More Information

Back